Seres Therapeutics Inc. announced that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President. In this newly created role, Hashad will be responsible for all activities related to the anticipated commercialization of the company's products in development, including SER-109, which is currently in a Phase 2 clinical study for recurring Clostridium difficile infection (CDI). He will report to Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres.

Hashad joins Seres with more than 25 years of experience successfully launching first- and best-in-class therapies for leading companies in the biotechnology and pharmaceutical industries, including Amgen, Boehringer Ingelheim and Lilly. Most recently, he was Vice President and Regional General Manager at Amgen, responsible for the Middle East and African region.